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ABSTRACT: The generation of a small and representative library of 3, 5, 8 - trisubstituted coumarins 
(21 compounds, 7 families, 3 groups) is described. The library was built from the corresponding propar-
gyl vinyl ethers and three different 1,3-dicarbonyl derivatives using a one pot coupled domino strategy. 
These coumarins constitute a novel chemotype defined by the presence of a chemical handle in the py-
ranone ring and a varied substitution pattern adorning the aromatic ring, which includes fluorine or oxy-
gen-containing functionalities. 
Coumarins (2H-benzo-pyran-2-ones) comprise a large family of natural scaffolds provided with a broad 
spectrum of biological and pharmaceutical activities
1
 and a privileged array of physicochemical proper-
ties such as a high capacity of fluorescence,
2
 which has been conveniently exploited in analytical chem-
istry, biology and medicine.
3
 In general, the substitution pattern decorating these scaffolds largely de-
termines their activity profiles
1
 and modulates their physicochemical properties.
4
 Thus, novel substitu-
tion patterns could offer novel pharmacological (therapeutic) annotations and novel biological and phys-
icochemical properties.
3,5
 From a chemical point of view, the access to novel coumarin chemotypes can 
be achieved either by chemical modifications of an existing one
6
 or by de novo synthesis from suitable 
precursors. Where the first approach usually requires chemoselective manipulation of functional groups, 
2 
 
the second one calls for a synthetic methodology capable of directly constructing the coumarin core 
with the appropriate substitution pattern already installed. This approach offers new opportunities for 
synthetic innovation and very especially for the development of novel domino methodologies for using 
in drug discovery and development. With this idea in mind, we report herein our results in the develop-
ment of a fast, operationally simple, one-pot coupled domino manifold for accessing novel 3, 5, 8 - tri-
substituted coumarins 3 from readily available  propargyl vinyl ethers 1 (Scheme 1). 
 
 
Scheme 1. Synthetic access to 3, 5, 8-trisubstituted coumarins 3. 
 
The substitution pattern involving the positions C3, C5 and C8 (Scheme 1) is scarcely represented in 
the series of both natural and synthetic coumarins
7
 and its biological (therapeutic) annotation has not 
been conveniently studied. The main reason for this lack of information is the challenging access to this 
family of trisubstituted coumarins by standard synthetic methodologies. In general, coumarins are cur-
rently synthesized from the corresponding phenolic derivatives
8
 conveniently functionalized (generally 
functionalized salicylaldehydes) by condensation with a suitable carbonyl derivative (Scheme 1).
1,8
 The 
main limitation associated with these strategies lies on their lack of generality and efficiency; not all of 
the positions of the aromatic and pyranone rings can be accessed from readily obtained  salicylalde-
hydes. This issue directly translates the problem of coumarin functionalization to the corresponding par-





Recently, our group described a diversity-oriented domino synthesis of 3, 6 
- disubstituted salicylaldehyde, derivatives 2 from propargyl vinyl ethers 1 (PVEs) (Scheme 2).
10
 We 
envisioned that these structures could be serve as suitable starting materials for the synthesis of 3, 5, 8 - 
trisubstituted coumarins 3 through a domino Knoevenagel condensation/lactonization reaction with an 
appropriated carbonyl derivative. Therefore, this strategy would allow us to perform the whole trans-
formation in one pot directly from the PVE with a good overall efficiency (Scheme 2). (Domino I: 
[3,3]-sigmatropic rearrangement - diene isomerization - enolization - 6-electro-cyclization; Domino II: 
Knoevenagel condensation - lactonization).  
 
 




From our previous studies on the salicylaldehyde formation reaction (Scheme 2),
10
 we knew that 
the in situ produced methanol (one equivalent of methanol is generated in the formation of salicylalde-
hyde 2) had to be removed from the reaction media to avoid the competitive formation of alkene 7, 
which is generated by methanol addition on 5 and redox rearrangement of the resulting hemiacetal.
11
 
This redox process could be avoided by using activated powdered molecular sieves 4Ǻ (MS 4Ǻ) as an 
additive. A fortuitous discovery showed us that also pyridine, a nucleophilic base, inhibited the for-
mation of the alkene.
7
 It is not easy to imagine pyridine as a methanol scavenger; instead, we believe 
that both additives assist in the enolization of intermediate 5 to give triene 6 which is not a suitable elec-
trophile for methanol. If intermediate 5 is quickly enolized, then its concentration will be maintained 
low and the formation of alkene 7 will be inhibited or severely diminished. There are precedents for the 
enolization of nitroalkanes aided by MS 4Ǻ.12 We found that the microwave irradiation of a solution of 
PVE 1 in xylene (1 mmol/1ml) [200 ºC, 300 W, 1h, closed vessel] in the presence of two equivalents of 
pyridine afforded the corresponding salicylaldehydes 2 with a comparable efficiency to the same pro-
cess in the presence of MS 4Ǻ (Table 1). Whereas pyridine offers a similar or slightly lower efficiency 
than MS 4Ǻ for substrates involving an aromatic or an ester group (diene activating groups) (entries 1-
4), it is the best option in the case of alkyl substitution at the terminal and propargylic positions (entry 
5). It is noteworthy that in these cases pyridine offers a clear advantage over MS 4Ǻ either in terms of 
instrumental simplicity (the reaction is performed under homogeneous conditions) and yields (54% ver-
sus 44%). Oxygen-containing and fluoride-containing derivatives can be accessed with pyridine as addi-
tive in fairly good yields (entries 6 and 7).  
Once the pyridine-assisted reaction could be standardized, we went one step further and we studied 











 2 Py (%)
a
   MS 4Ǻ (%)a,b  
1 Ph Et a 75 76 
2 Ph Ph b 80 89 
3 Ph tBu c 53 67 
4 CO2Me Pr d 56 70 
5 Bu Et e 54 44 
6 Ph F f 61 63 
7 Ph OBn g 70 -- 
  
a
Yield of isolated compounds. 
b
See Rf. 10.   
 
substituents at the C3 position. For this transformation we explored a domino Knoevenagel condensa-
tion/lactonization protocol,
1,8
  involving 1,3-dicarbonyl derivatives armed with at least one ester group  
and salicylaldehydes 2a-g. This domino reaction can be base-catalyzed (through the formation of the 
enolate anion of the active methylene derivative) or iminium-catalyzed (through the formation of the 
corresponding iminium ion derivative of the aromatic aldehyde).
13
 As a first approximation, we chose 
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the base catalyzed version in hopes that we would be able to connect this domino reaction with the pyri-
dine-assisted domino formation of salicylaldehydes 2 (Scheme 2). After several experimental attempts 
using different malonate derivatives, different bases and different reaction conditions (temperature, sol-
vent), we were unable to run the whole process directly from the PVE: the set of experimental condi-
tions that sparked a domino process were unfavorable for the other and vice versa.  Thus, we turned our 
attention to a one pot strategy. We explored this possibility using the iminium catalyzed conditions for 
the Knoevenagel reaction.
13
 After several experimental attempts using different catalysts and conditions, 
we arrived to piperidinium acetate (PPA) (5 mol%) as the best catalyst and refluxing ethanol as the 
more convenient reaction conditions. The one pot process could be performed by first running the mi-
crowave-assisted formation of the salicylaldehyde intermediate 2 and then, once the solvent and base 
were distilled off, running the second domino reaction on the crude reaction residue. 
For this study, we chose three different carbonyl derivatives, i.e. ethyl acetoacetate, Meldrum’s acid 
and ethyl cyanoacetate, to generate the corresponding coumarins 3 armed with an ester, acid or nitrile 
group at the C3 position. Each Knoevenagel reaction required a fine tuning of the experimental condi-
tions to be performed with synthetic efficiency (Scheme 3; conditions A, B and C). Ethyl acetoacetate 
reacted with salicylaldehydes 2a-g (conditions A) to afford the corresponding 3-acyl-coumarins 3ab-gb 
in good overall yields (70% average yield per domino process). The more reactive Meldrum’s acid re-
quired more catalyst (20 mol%)(conditions B) to be transformed into the corresponding coumarins 3ac-
gc with moderate to good efficiency (overall yields span from a modest 30% to a fairly good 57%). The 
less reactive and less acidic ethyl cyanoacetate required catalysis and microwave irradiation [100 ºC, 
300 W, 1h, closed vessel] (conditions C) to accomplish this transformation.  Under these conditions, it 
afforded the corresponding coumarins 3aa-ga featuring a chemically versatile nitrile group at C3.
14






= Ac, EtOH (3 ml), PPA (5 mol%), reflux, 16h. (B): Meldrum's acid, EtOH (3 ml), PPA (20 
mol%), reflux, 2h. (C): R
3
 = CN, [100 ºC, 300 W], xylene (1 ml), PPA (5 mol%); 1h, closed vessel. 




should be noted that the substituents at the C3 and C6 positions of salicylaldehydes 2a-g exercise an im-
portant steric impediment to these reactions, which translates to the overall yield of the process, slightly  
lower than those reported for salicylaldehyde derivatives with these positions free of substitution.
1,8
 Last 
but not least, coumarins armed with a fluorine atom (3fa-fc) or an oxygen-containing functionality (3ga-
gc) at the C8 position can be generated in good overall yields under conditions A and B and with lower 
efficiency under conditions C. 
In summary, we have generated a representative library of 21 different 3, 5, 8- trisubstituted couma-
rins grouped in 7 families of 3 members each. This representative library was built using a one pot cou-
pled domino process manifold. The one pot process takes advantage of the fortuitous discovery of the 
pyridine-aided domino generation of salicylaldehydes 2 under microwave irradiation. This instrumental-
ly simple coupled domino manifold allows for the fast access to a novel coumarin chemotype defined by 
its substitution pattern at the aromatic ring (C5, C8 - functionalization). These chemotypes feature a 
chemical handle in the pyranone ring (C3-position) for further elaboration and a diverse substitution 





H NMR and 
13
C NMR spectra of CDCl3 solutions were recorded either at 400 
and 100 MHz or at 500 and 125 MHz, respectively. Microwave reactions were conducted in sealed glass 
vessels (capacity 10 mL) using a CEM Discover microwave reactor equipped with a surface sensor for 
temperature measuring of the reaction mixture. FT-IR spectra were measured in chloroform solutions 
using a FT-IR spectrophotometer. Mass spectra (low resolution) (EI/CI) and HRMS (EI/TOF) were ob-
tained with a gas chromatograph/mass spectrometer. Analytical thin-layer chromatography plates used 
UV-active silica on aluminum. Flash column chromatography was carried out with silica gel of particle 
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size less than 0.020 mm, using appropriate mixtures of ethyl acetate and hexanes as eluents. All reac-
tions were performed in oven-dried glassware. All materials were obtained from commercial suppliers 
and used as received unless otherwise noted. Propargyl vinyl ethers (PVEs) were synthesized according 




 When not commercially available, the propargyl alco-
hols were prepared by addition of the lithium acetylides onto the appropriate aldehydes following the 
literature procedure.
17
 All other materials were obtained from commercial suppliers and used as re-




Synthesis of (E)-Methyl 3-(1-(benzyloxy)-4-phenylbut-3-yn-2-yloxy)acrylate (1g). Triethylamine 
(0.30 mmol) was added to a solution of methyl propiolate (3.0 mmol) and 1-(benzyloxy)-4-phenylbut-3-
yn-2-ol (3.0 mmol) in dry CH2Cl2 (10 ml). The reaction mixture was stirred for 2 h. After removing the 
solvent at reduced pressure the products were purified by flash column chromatography (silica gel, n-
hexane/EtOAc 90/10) to yield 1g (959 mg; 89%) (gummy oil): 
1
H NMR (CDCl3, 400 MHz):   3.70 
(s, 3H), 3.82-3.84 (m, 2H), 4.61 (d, 
3
J(H,H) = 12.1 Hz, 1H), 4.67 (d, 
3
J(H,H) = 12.1 Hz, 1H), 4.97 (t, 
3
J(H,H) 
= 5.8 Hz, 1H), 5.46 (d, 
3
J(H,H) =  12.6 Hz, 1H), 7.28-7.36 (m, 8H), 7.41-7.44 (m, 2H), 7.70 (d, 
3
J(H,H) = 
12.6 Hz, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 51.1, 71.9, 73.6, 82.5, 88.9, 98.9, 121.5, 127.8, 
127.9, 128.4, 128.5, 129.1, 131.9, 137.5, 160.6, 167.9 ppm. FTIR (CHCl3): 3065.5, 3028.1, 3014.9, 





 + Na] Calcd  for C21H20O4Na 359.1259. Found 359.1259. 
Representative procedure for the microwave-assisted rearrangement of propargyl vinyl ether 1 in 
the presence of pyridine. Synthesis of salicylaldehydes 2. Propargyl vinyl ether 1g (1.00 mmol), o-
xylene (1 mL) and pyridine (2.00 mmol) were placed in a microwave-special closed vial and the solu-
tion was irradiated for 1 hour in a single-mode microwave oven (300 Watt, 200 ºC). After removing the 
solvent at reduced pressure the products were purified by flash column chromatography (silica gel, ap-
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propriate mixtures of ethyl acetate / hexane) to yield 2g (212.8 mg; 70%). Amorphous solid. 
1
H NMR 
(CDCl3, 400 MHz):  5.23 (s, 2H), 6.76 (d, 
3
J(H,H) = 8.3 Hz, 1H), 7.13 (d, 
3
J(H,H) = 8.33 Hz, 1H), 7.31-
7.37 (m, 3H), 7.41-7.48 (m, 7H), 9.83 (s, 1H), 12.18 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 
71.6, 18.3, 120.7, 120.8, 127.4, 127.9, 128.1, 128.4, 128.7, 130.2, 136.7, 137.5, 139.5, 146.7, 153.7, 
197.6 ppm; FTIR (CHCl3): 3027.9, 2887.2, 1644.1, 1570.6, 1449.3, 1393.5 cm
-1
; LRMS (70 eV) 
m/z (%): 304 (7.2) [M
+
], 139 (8.2), 128 (10), 91 (100). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for C20H16O3 
304.1107; Found 304.1099. 
Representative procedure for the synthesis of coumarins bearing an acetate at the 3-position 
(Conditions A). Propargyl vinyl ether 1a (1.00 mmol), o-xylene (1 mL) and pyridine (2.00 mmol) were 
placed in a microwave-special closed vial and the solution was irradiated for 1 hour in a single-mode 
microwave oven (300 Watt, 200 ºC). After the time described, the sample was cooled to room tempera-
ture and the crude of the reaction was redissolved in 3 mL of ethanol. Ethyl acetoacetate (1.1 mmol) and 
piperidine (0.05 mmol) were added and the solution was refluxed during 20 hours. After that time, the 
solvent was removed at reduced pressure. The products were purified by flash column chromatography 
(silica gel, appropriate mixtures of dichloromethane / hexane) to yield 3aa (204.4 mg; 70%). 
3-Acetyl-8-ethyl-5-phenyl-2H-chromen-2-one (3aa). Amorphous solid. 
1
H NMR (CDCl3, 400 MHz): 
 1.33 (t, 3J(H,H) = 7.6 Hz, 3H), 2.68 (s, 3H), 2.94 (q, 
3
J(H,H) = 7.58 Hz, 2H), 7.23 (d, 
3
J(H,H) = 7.6 Hz, 
1H), 7.31-7.33 (m, 2H), 7.44-7.49 (m, 3H), 7.53 (d, 
3
J(H,H) = 7.6 Hz, 1H), 8.53 (s, 1H) ppm. 
13
C NMR 
(CDCl3, 100 MHz): = 14.0, 22.5, 30.5, 116.2, 123.9, 125.7, 128.4, 129.8, 131.1, 133.6, 137.6, 141.8, 
146.4, 153.8, 159.1, 195.7 ppm. FTIR (CHCl3): 3025.9, 2974.9, 2877.3, 1954.9, 1905.8, 1729.9, 
1688.3, 1581.5 cm
-1
. Anal. Calcd for C19H16O3: C, 78.06; H, 5.52. Found: C, 77.8; H, 5.69.  LRMS (70 
eV) m/z (%): 292 (90) [M
+
], 277 (100), 249 (33) 235 (13), 207 (16), 193 (13), 178 (29), 165 (22), 152 
(10), 84 (34).  
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3-Acetyl-5,8-diphenyl-2H-chromen-2-one (3ba). (227.8 mg; 67%). Amorphous solid. 
1
H NMR 
(CDCl3, 400 MHz): sm, 3H), 7.44- 7.45 (m, 1H), 7.49-7.55(m, 5H), 7.64-
7.67 (m, 2H), 7.72 (t, 
3
J(H,H) = 7.83, 1H), 8.59 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 30.4, 
116.8, 124.1, 125.9, 128.3, 128.6 (2C), 128.7, 128.9, 129.2, 129.5 (2C), 129.8 (2C), 134.8, 135.2, 137.4, 
143.3, 146.2, 152.7, 158.6, 195.5 ppm.  FTIR (CHCl3): 3025.3, 1736.2, 1690.0, 1584.7, 1574.8 cm
-
1
. LRMS (70 eV) m/z (%): 340 (100) [M
+
], 325 (64), 297 (21), 239 (38), 230 (18), 129 (8.5), 115 (11), 
83 (32). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for C23H16 O3 340.1099; Found 340.1109.  
3-Acetyl-8-tert-butyl-5-phenyl-2H-chromen-2-one (3ca). (121.6 mg; 38%). Amorphous solid. 
1
H 
NMR (CDCl3, 400 MHz): ss, 3H), 7.23 (d, 
3
J(H,H) = 8.1 Hz, 1H), 7.31-7.34 (m, 
2H), 7.45-7.51(m, 3H), 7.66 (d, 
3
J(H,H) = 8.1 Hz, 1H), 8.55 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): 
= 29.8, 30.5, 35.0, 116.9, 123.2, 125.5, 128.4, 128.8, 129.8, 131.5, 136.9, 137.5, 142.1, 146.7, 154.6, 
158.6, 195.5 ppm. FTIR (CHCl3): 3694.7, 3026.5, 3013.6, 2963.9, 2928.8, 2874.8, 2857.0, 1726.4, 
1688.3, 1602.3, 1574.3 cm
-1
. LRMS (70 eV) m/z (%): 320 (45) [M
+
], 305 (72), 221 (100), 189 (8.4), 
165 (12). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for C21H20 O3 320.1412; Found 320.1405. 
Methyl 3-acetyl-2-oxo-8-propyl-2H-chromene-5-carboxylate (3da). (115.2 mg; 40%). Amorphous 
solid.
 1
H NMR (CDCl3, 400 MHz):  0.99 (t, 
3
J(H,H) = 7.3 Hz, 3H), 1.68-1.77 (m, 2H) 2.72 (s, 3H), 
2.88 (q, 
3
J(H,H) = 7.6 Hz, 2H), 3.97 (s, 3H), 7.51 (d, 
3
J(H,H) = 7.8 Hz, 1H), 7.89 (d, 
3
J(H,H) = 7.8 Hz, 1H), 
9.54 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 13.8, 22.6, 30.3, 31.7, 52.6, 117.5, 125.5, 127.3, 
127.4, 133.3, 135.6, 145.5, 153.9, 158.1, 165.8, 195.4 ppm. FTIR (CHCl3): 3087.2, 3027.5, 2963.8, 
2874.9, 1728.1, 1693.6, 1613.9, 1585.6, 1566.4, 1480.2, 1436.0, 1415.8 cm
-1
. LRMS (70 eV) m/z (%): 
288 (43) [M
+
], 273 (100), 259 (11), 217 (5.4), 189 (4.5), 115 (6.6), 102 (4.3), 77 (3.1). HRMS (EI-TOF) 
m/z: [M]
+
 Calcd  for C16H16 O5 288.0998; Found 288.1000. 
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 3-Acetyl-5-butyl-8-ethyl-2H-chromen-2-one (3ea). (114.2 mg; 42%). Amorphous solid. 
1
H NMR 
(CDCl3, 400 MHz):  0.94 (t, 
3
J(H,H) =  7.3 Hz, 3H), 1.27 (t, 
3
J(H,H) = 7.6 Hz, 3H), 1.34-1.44 (m, 2H), 
1.60-1.64 (m, 2H), 2.73 (s, 3H), 2.82-2.90 (m, 4H), 7.07 (d, 
3
J(H,H) = 7.6 Hz, 1H), 7.40 (d, 
3
J(H,H) = 7.8 
Hz, 1H), 8.43 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 13.8, 13.9, 22.3, 22.4, 30.5, 30.6, 34, 
116.5, 123.2, 125.0, 129.7, 133.9, 141.4, 144.7, 154.0, 159.2, 195.8 ppm. FTIR (CHCl3): 3027.6, 
2962.2, 2935.1, 2875.1, 1725.7, 1686.7, 1586.2, 1566.8, 1481.7 cm
-1
. LRMS (70 eV) m/z (%): 272 (93) 
[M
+
], 257 (100), 229 (72), 215 (17), 201 (20), 187 (12), 173 (8.1), 128 (14), 115 (25), 91 (12). HRMS 
(EI-TOF) m/z: [M]
+
 Calcd  for C17H20 O3 272.1411; Found 272.1412. 
3-Acetyl-8-fluoro-5-phenyl-2H-chromen-2-one (3fa). (115.6 mg; 41%). Amorphous solid. 
1
H NMR 
(CDCl3, 400 MHz): s, 3H), 7.25 (dd, 
3
J(H,H) = 8.3 Hz, 4.6, 1H), 7.31-7.33  (m, 2H), 7.42-7.50 
(m, 4H), 8.47 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 30.4, 118.0, 120.0 (JCF = 17.0), 125.0, 
125.6 (JCF = 5.7), 128.7, 128.9, 129.7, 136.7, 139.5 (JCF = 4.2), 143.7 (JCF = 11.3), 145.6, 148.4 (JCF = 
253.6), 157.6, 195.1 ppm.  FTIR (CHCl3): 3026.9, 1887.3, 1693.2, 1604.6, 1571.3 cm
-1
. LRMS (70 
eV) m/z (%): 282 (74) [M
+
], 267 (100), 238 (45), 212 (12), 183 (87), 163 (13), 157 (11), 84 (66). HRMS 
(EI-TOF) m/z: [M]
+
 Calcd  for C17H11FO3 282.0692; Found 282.0688. 
3-Acetyl-8-(benzyloxy)-5-phenyl-2H-chromen-2-one (3ga). (236.8 mg; 64%). Amorphous solid. 
1
H 
NMR (CDCl3, 400 MHz):  2.69 (s, 3H), 5.30 (s, 2H), 7.17-7.51 (m, 12H), 8.51 (s, 1H) ppm. 
13
C 
NMR (CDCl3, 100 MHz): = 30.4, 71.5, 117.2, 118.1, 124.4, 125.5, 127.3, 128.1, 128.2, 128.7, 128.8, 
129.8, 135.8, 136.1, 137.3, 145.2, 145.9, 146.2, 158.5, 195.6 ppm. FTIR (CHCl3):  3064.9, 3028.2, 
3015.6, 2931.0, 1733.4, 1690.1, 1612.6, 1592.2, 1561.7 cm
-1
. LRMS (70 eV) m/z (%): 370 (3.6) [M
+
], 
237 (1.9), 176 (4.9), 152 (10), 129 (22), 115 (12), 91 (100), 77 (10), 65 (16). HRMS (EI-TOF) m/z: 
[M]
+
 Calcd  for C24H18O4 370.1205; Found 370.1193. 
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Representative procedure for the synthesis of coumarins bearing a carboxylic acid at the 3-
position. (Conditions B). Propargyl vinyl ether 1a (1.00 mmol), o-xylene (1 mL) and pyridine (2.00 
mmol) were placed in a microwave-special closed vial and the solution was irradiated for 1 hour in a 
single-mode microwave oven (300 Watt, 200 ºC). After removing the solvent at reduced pressure the 
products were redissolved in ethanol. Meldrum acid (1.1 mmol) and piperidinium acetate (0.2 mmol) 
were added. The solution was refluxed with stirring during 2 hours. The solvent was removed at reduced 
pressure. The products were purified by flash column chromatography (silica gel, appropriate mixtures 
of dichloromethane/MeOH) to yield 3ab (138.2 mg; 47%). 
8-ethyl-2-oxo-5-phenyl-2H-chromene-3-carboxylic acid (3ab). Amorphous solid. 
1
H NMR (CD3OD, 400 
MHz 1.29 (t, 3J(H,H) = 7.6 Hz, 3H), 2.9 (q, 
3
J(H,H) = 7.6 Hz, 2H), 7.28 (d, 
3
J(H,H) = 7.3 Hz, 1H), 7.36-
7.38 (m, 2H), 7.44-7.48 (m, 3H), 7.6 (d, 
3
J(H,H) = 7.6 Hz, 1H), 8.6 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 
MHz): 19.4, 22.5, 116.7, 126.8, 128.7, 129.0, 129.8, 131.6, 134.7, 136.9, 142.1, 150.2, 153.0, 163.2, 
163.6 ppm. FTIR (CHCl3):   3070.1, 2995.6, 2949.7, 2914.3, 1757.6, 1680.9, 1590.0, 1473.9 cm
-1
. 
Anal. Calcd for C18H14O4: C, 73.46; H, 4.79. Found: C, 73.56; H, 4.60. LRMS (70 eV) m/z (%): 
294(100) [M
+
], 279 (16), 250(71), 235 (47), 207 (37), 193 (26), 178 (43), 165 (30), 152 (20), 115 (15), 
89 (13), 84 (12), 77 (11). 
2-Oxo-5,8-diphenyl-2H-chromene-3-carboxylic acid (3bb). (143.6 mg; 42%). Amorphous solid. 
1
H 
NMR (CDCl3, 400 MHz):  7.40 (d, 
3
J(H,H) = 7.1 Hz, 2H), 7.45-7.55 (m, 7H), 7.62 (d, 
3
J(H,H) = 7.3 Hz, 
2H), 7.84 (d, 
3
J(H,H) = 7.8 Hz, 1H), 9.03 (s, 1H), 12.14 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 
114.3, 117.2, 127.1, 128.6, 128.8 (2C), 129.1, 129.2 (2C), 129.4 (2C), 129.7 (2C), 129.8, 134.5, 136.2, 
136.7, 143.7, 150.5, 151.9, 162.5, 163.6 ppm. FTIR (CHCl3):  3692.4, 3063.9, 3027.8, 2962.7, 
1758.9, 1682.1, 1590.8, 1471.5, 1453.8, 1397.6 cm
-1
). LRMS (70 eV) m/z (%): 342 (100) [M
+
], 298 
(30), 270 (19), 256 (14), 239 (34), 133 (12),129 (28), 128 (17). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for 
C22H14O4 342.0892; Found 342.0886. 
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8-tert-Butyl-2-oxo-5-phenyl-2H-chromene-3-carboxylic acid (3cb). (138.5 mg; 43%). Amorphous 
solid. 
1
H NMR (CD3OD, 400 MHz): 1.49 (s, 9H), 7.28 (d, 
3
J(H,H) = 7.6 Hz, 1H), 7.35-7.37 (m, 2H), 
7.45-7.48 (m, 3H), 7.74 (d, 
3
J(H,H) = 7.6 Hz, 1H), 8.63 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 
29.8 (3C), 35.1, 117.3, 126.6, 128.7, 128.9 (2C), 129.7 (2C), 132.8, 136.8, 137.4, 142.5, 150.7, 153.8, 
163.34, 163.38 ppm. LRMS (70 eV) m/z (%): 322 (51) [M
+
], 307 (67), 221 (100), 178 (12)165 (14), 84 
(29). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for C20H18O4 322.1205; Found 322.1201. 
5-(Methoxycarbonyl)-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (3db). (107.3 mg; 37%). 
Amorphous solid. 
1
H NMR (CDCl3, 400 MHz): 1.00 (t, 
3
J(H,H) = 7.3 Hz, 3H), 1.69-1.79 (m, 2H), 
2.92 (q, 
3
J(H,H) = 8.1 Hz, 2H), 4.00 (s, 3H), 7.64 (d, 
3
J(H,H) = 8.09 Hz, 1H), 8.02 (d, 
3
J(H,H) = 7.83 Hz, 
1H), 10.03 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): =13.8, 22.6, 31.6, 52.9, 115.7, 117.7, 127.6, 
128.5, 134.8, 136.2, 150.1, 153.2, 162.2, 163.1, 165.3 ppm. FTIR (CHCl3): 3030.4, 2996.9, 2957.9, 
2935.3, 1757.7, 1723.0, 1686.0, 1620.9, 1588.5, 1484.4, 1437.1, 1398.6 cm
-1
.  Anal. Calcd for 
C15H14O6: C, 62.07; H, 4.86. Found: C, 62.31; H, 4.83. LRMS (70 eV) m/z (%): 290 (29) [M
+
], 261 
(36), 246 (100), 232 (27), 217 (18), 189 (11), 161 (10), 115  
5-Butyl-8-ethyl-2-oxo-2H-chromene-3-carboxylic acid (3eb). (74 mg; 27%). Amorphous solid. 
1
H 
NMR (CDCl3, 400 MHz):  0.95 (t, 
3
J(H,H) = 7.3 Hz, 3H), 1.29 (t, 
3
J(H,H) = 7.6 Hz, 3H), 1.34-1.45 (m, 
2H), 1.58-1.66 (m, 2H), 2.86-2.95 (m, 4H),   7.20 (t, 
3
J(H,H) = 7.6 Hz, 1H), 7.52 (t, 
3
J(H,H) = 7.6 Hz, 1H), 
9.14 (s, 1H), 12.42 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 13.8, 13.9, 22.3, 22.4, 31.6, 34.1, 
113.4, 117.0, 126.3, 130.3, 135.4, 142.0, 148.7, 135.3, 163.0, 164.1ppm. FTIR (CHCl3): 3029.2, 
2962.1, 2934.8, 2875.7, 1753.7, 1681.1, 1593.7, 1402.8 cm
-1
. LRMS (70 eV) m/z (%): 274 (100) [M
+
], 
259 (21), 230 (72), 203 (18), 187 (13), 128 (21), 115 (35), 91 (15), 84 (89), 77 (12). HRMS (EI-TOF) 
m/z: [M]
+
 Calcd  for C16H18O4 274.1202; Found 274.1205. 
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8-Fluoro-2-oxo-5-phenyl-2H-chromene-3-carboxylic acid (3fb). (133.5 mg; 47%). Amorphous solid. 
1H NMR (CDCl3, 400 MHz): 7.32-7.33 (m, 2H), 7.38 (dd, 3J(H,H) = 8.3 Hz, 4.0, 1H), 7.52-7.60 (m, 
4H), 8.93 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 115.4, 118.2, 121.3 (JCF = 16.2 Hz), 126.8 
(JCF = 5.7 Hz), 129.1, 129.2, 129.7, 136.0, 139.9 (JCF = 4.2 Hz), 142.9 (JCF = 12.0 Hz), 148.5 (JCF = 255 
Hz), 150, 161.9, 162.5. FTIR (CHCl3): 3619.9, 3464.4, 3015.7, 2976.8, 2928.5, 1759.9, 1699.3, 
1687.0, 1608.9, 1582.8 cm
-1
. LRMS (70 eV) m/z (%): 284 (37) [M
+
], 240 (44), 212 (33), 198 (21), 183 
(100), 181 (23), 163 (17), 157 (12), 97 (15), 83 (27), 69 (37), 55 (62). HRMS (EI-TOF) m/z: [M]
+
 Calcd  
for C16H9FO4 284.0485; Found 284.048. 
8-(Benzyloxy)-2-oxo-5-phenyl-2H-chromene-3-carboxylic acid (3gb). (212 mg; 57%). Amorphous 
solid. 
1
H NMR (CDCl3, 400 MHz):  5.32 (s, 2H), 7.28-7.51 (m, 12H), 8.94 (s, 1H), 12.1 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 71.7, 114.6, 117.6, 118.9, 126.8, 127.4, 128.5, 128.6, 128.9, 129.1, 
130.7, 135.6, 136.0, 136.7, 144.6, 145.5, 150.5, 162.5, 163.6 ppm. FTIR (CHCl3): 3694.2, 3601.2, 
3029.8, 3012.2, 1756.8, 1682.5, 1598.4, 1564.3 cm
-1
. LRMS (70 eV) m/z (%): 372 (9.3) [M
+
], 333 (4.1), 
282 (6.9), 181 (5.7), 152 (21), 91 (100). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for C23H16O5 372.0998; 
Found 372.0992. 
Representative procedure for the synthesis of coumarins bearing a cyano group at the 3-position. 
(Conditions C). Propargyl vinyl ether 1a (1.00 mmol), o-xylene (1 mL) and pyridine (2.00 mmol) were 
placed in a microwave-special closed vial and the solution was irradiated for 1 hour in a single-mode 
microwave oven (300 Watt, 200 ºC). After the time described the sample was cooled to room tempera-
ture. Ethyl cyanoacetate (1.1 mmol) and piperidine (0.05 mmol) were added and the solution was heated 
to 100ºC (300 Watt), during 1 hour. The solvent was then removed at reduced pressure. The products 
were purified by flash column chromatography (silica gel, appropriate mixtures of dichloro-
methane/hexane) to yield 3ac (149.9 mg; 57%).  
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8-Ethyl-2-oxo-5-phenyl-2H-chromene-3-carbonitrile (3ac). Amorphous solid. 
1
H NMR (CDCl3, 400 
MHz):  1.33 (d, 3J(H,H) = 7.6 Hz, 3H), 2.92 (q, 
3
J(H,H) = 7.6 Hz, 2H), 7.29-7.32 (m, 3H), 7.49-7.55 (m, 
3H), 7.60 (d, 
3
J(H,H) = 7.8 Hz, 1H), 8.28 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 13.9, 22.4, 
102.4, 113.9, 115.4, 126.3, 128.8, 129.0, 129.7, 131.9, 134.8, 136.8, 140.9, 151.0, 153.1, 156.4 ppm. 
FTIR (CHCl3):3064.1, 3026.8, 2973.9, 2934.1, 2876.7, 2236.1, 1906.8, 1743.0, 1588.6, 1473.5, 
1215.9 cm
-1
. Anal. Calcd for C18H13NO2 : C, 78.53; H, 4.76; N, 5.09. Found: C, 78.58; H, 4.76; N, 5.16. 
LRMS (70 eV) m/z (%): 275 (100) [M
+
], 260 (90), 193 (18), 165 (17).  
2-Oxo-5,8-diphenyl-2H-chromene-3-carbonitrile (3bc). (161.5 mg; 50%). Amorphous solid. 
1
H NMR 
(CDCl3, 400 MHz):  7.36-7.61 (m, 11H), 7.7 (d, 
3
J(H,H) = 7.8 Hz, 1H), 8.34 (s, 1H) ppm. 
13
C NMR 
(CDCl3, 100 MHz): = 102.7, 113.8, 115.9, 126.5, 128.5, 128.7 (2C), 129.0, 129.1 (2C), 129.4 (2C), 
129.7 (2C), 129.9, 134.5, 136.1, 136.6, 142.7, 150.9, 151.9, 155.8 ppm. FTIR (CHCl3):3692.0, 
3026.3, 2928.2, 2855.6, 2239.6, 1745.6, 1589.9, 1470.4 cm
-1
. LRMS (70 eV) m/z (%): 323 (100) [M
+
], 
294 (12), 266 (13), 239 (11), 190 (6.80), 164 (3.30), 128 (8.10), 119 (4.60), 63 (3.90). HRMS (EI-TOF) 
m/z: [M]
+
 Calcd  for C22H13N O2 323.0946; Found 323.0937. 
8-tert-Butyl-2-oxo-5-phenyl-2H-chromene-3-carbonitrile (3cc). (160.6 mg; 53%). Amorphous solid. 
1
H NMR (CDCl3, 400 MHz): 1.53 (s, 9H), 7.28 (d, 
3
J(H,H) = 8.1 Hz, 1H), 7.30-7.32 (m, 2H), 7.51-
7.53 (m, 3H), 7.72 (d, 
3
J(H,H) = 8.1 Hz, 1H), 8.28 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 29.8, 
35.1, 101.8, 113.9, 116.0, 126.0, 128.8, 129.0, 129.7, 132.7, 136.8, 137.7, 141.3, 151.3, 153.9, 155.8 
ppm. FTIR (CHCl3):3692.6, 3063.7, 3025.1, 2963.8, 2876.3, 2237.4, 1742.5, 1618.5, 1582.9 cm
-1
. 
LRMS (70 eV) m/z (%): 303 (26) [M
+
], 288 (94), 259 (16), 229 (38), 221 (42), 197 (66), 187 (17), 175 
(18), 170 (11), 142 (20), 131 (31), 103 (11), 88 (11), 84 (100), 77 (11), 57 (51). HRMS (EI-TOF) m/z: 
[M]
+
 Calcd  for C20H17N O2 303.1259; Found 303.1257.  
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Methyl 3-cyano-2-oxo-8-propyl-2H-chromene-5-carboxylate (3dc).  (89.4 mg; 33%). Amorphous 
solid. 
1
H NMR (CDCl3, 400 MHz): 0.98 (t, 
3
J(H,H) = 7.3 Hz, 3H) 1.66-01.75 (m, 2H), 2.86 (t, 
3
J(H,H) 
= 7.8 Hz, 2H) 3.98 (s, 3H), 7.58 (d, 
3
J(H,H) =  7.8 Hz, 1H), 7.98 (t, 
3
J(H,H) = 7.8 Hz, 1H), 9.59 (s, 1H) 
ppm. 
13
C NMR (CDCl3, 100 MHz): = 13.8, 22.6, 31.6, 52.9, 104.4, 113.6, 116.6, 125.9, 128.1, 134.7, 
136.6, 150.5, 153.4, 155.5, 165.4 ppm. FTIR (CHCl3):3092.7, 3028.0, 3001.9, 2961.4, 2934.6, 
2875.3, 2237.3, 1742.9, 1720.9, 1618.7, 1586.8, 1482.3, 1436.3 cm
-1
. LRMS (70 eV) m/z (%): 271 (71) 
[M
+
], 242 (100), 212 (9.8), 155 (6.5), 127 (7.10), 84 (27), 55 (7.2).  HRMS (EI-TOF) m/z: [M]
+
 Calcd  
for C15H13N O4 271.0845; Found 271.0837. 
5-Butyl-8-ethyl-2-oxo-2H-chromene-3-carbonitrile (3ec). (56.1 mg; 22%). Amorphous solid. 
1
H 
NMR (CDCl3, 400 MHz):  0.95  (t, 
3
J(H,H) = 7.1 Hz, 3H), 1.25  (t, 
3
J(H,H) = 7.6 Hz, 3H), 1.36-1.45 (m, 
2H), 1.55-1.63 (m, 2H), 2.81-2.85 (m, 4H),   7.13 (d, 
3
J(H,H) = 7.6 Hz, 1H), 7.46 (d, 
3
J(H,H) = 7.8 Hz, 1H) 
8.45 (s, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 13.8, 13.9, 22.2, 22.5, 31.7, 34.1, 101.9, 114.1, 
115.6, 125.8, 130.5, 135.2, 140.5, 149.2, 153.3, 156.5 ppm. FTIR (CHCl3):3026.2, 2962.9, 2935.4, 
2875.6, 2234.7, 1910.8, 1880.2, 1739.7, 1591.8, 1483.8, 1463.1, 1438.0 cm
-1
. LRMS (70 eV) m/z (%): 
255 (65) [M
+
], 240 (30), 212 (100), 184 (28), 140 (13), 115 (15), 83 (22). HRMS (EI-TOF) m/z: [M]
+
 
Calcd  for C16H17N O2 255.1259; Found 255.1252.  
8-Fluoro-2-oxo-5-phenyl-2H-chromene-3-carbonitrile (3fc). (98.1 mg; 37%). Amorphous solid. 1H 
NMR (CDCl3, 400 MHz):  7.30-7.33 (m, 3H), 7.50-7.55 (m, 4H), 8.25 (d, 
3
J(H,H) = 1.3 Hz, 1H) ppm. 
13
C NMR (CDCl3, 100 MHz): = 103.8, 113.3, 116.9, 121.6 (JCF = 17.7 Hz), 126.3 (JCF = 6.4), 129.1, 
129.2, 129.7, 135.9, 138.7 (JC F= 4.2 Hz), 143.0 (JCF = 12.7 Hz), 148.5 (JCF = 255 Hz), 150.4, 154.7 
ppm. FTIR (CHCl3):3692.5, 3066.1, 3024.3, 2241.4, 1890.7, 1607.9, 1578.6 cm
-1
. LRMS (70 eV) 
m/z (%): 265 (100) [M
+
], 237 (35), 208 (47), 199 (19), 170 (24), 84 (51). HRMS (EI-TOF) m/z: [M]
+
 
Calcd  for C16H8FNO2 265.0539; Found 265.0540. 
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8-(Benzyloxy)-2-oxo-5-phenyl-2H-chromene-3-carbonitrile (3gc). (123.6 mg; 35%). Amorphous 
solid. 
1
H NMR (CDCl3, 400 MHz):  5.23 (s, 2H), 7.16-7.45 (m, 12H), 8.20 (s, 1H) ppm. 
13
C NMR 
(CDCl3, 100 MHz): = 71.6, 103.1, 113.8, 116.2, 119.1, 126.1, 127.4, 128.4, 128.6, 128.8, 129.0, 
129.8, 134.8, 135.7, 136.6, 145.2, 145.6, 150.9, 155.8 ppm. FTIR (CHCl3):3694.5, 3592.2, 3065.8, 
3025.2, 228.2, 1746.5, 1596.9, 1564.2 cm
-1
. LRMS (70 eV) m/z (%): 353 (1.8) [M
+
], 263 (1.7), 177 
(4.4), 151 (3.0), 91 (100). HRMS (EI-TOF) m/z: [M]
+
 Calcd  for C23H15NO3 353.1052; Found 
353.1064. 
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